Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Allogeneic CAR19 cells clear ALL

Paul Neeson

Blood (2016) 127 (10): 1224–1225.

https://doi.org/10.1182/blood-2016-01-687681

Published: 2016

Journal Articles

CAR-T Cells Are Serial Killers of Tumor Cells

Misty Jenkins, PhD, Alex Davenport, Ryan Cross, Carmen Yong, David S. Ritchie, MDPhD, Joe Trapani, Michael Kershaw, Phil Darcy, Paul Neeson, PhD

Blood (2015) 126 (23): 3088.

https://doi.org/10.1182/blood.V126.23.3088.3088

Published: 2015

Journal Articles

Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma

Misty Jenkins, PhD, Rachael Canfield, BSc, Michael Robbins, BS, David S. Ritchie, MDPhD, Joe Trapani, Paul Neeson, BSc, PhD

Blood (2015) 126 (23): 4237.

https://doi.org/10.1182/blood.V126.23.4237.4237

Published: 2015

Journal Articles

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation and Onset of Gvhd

Joanne E Davis, PhD, Michael Harvey, BSc(Hons), Nicholas A Gherardin, BSc(Hons), Rachel Koldej, PhD, Nicholas Huntington, PhD, Paul Neeson, PhD, Joseph A Trapani, PhD MBBS, FRACP, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 3805.

https://doi.org/10.1182/blood.V124.21.3805.3805

Published: 2014

Journal Articles

Histone Deacteylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells

Michael J. Dickinson, MBBS, FRACP, FRCPA, Alexander Davenport, Pasquale Petrone, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD, Paul Neeson, PhD

Blood (2013) 122 (21): 3495.

https://doi.org/10.1182/blood.V122.21.3495.3495

Published: 2013

Journal Articles

CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicty

Andy K Hsu, PhD, Nick Gherardin, BSc Hons, Hang Quach, MBBS MD, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD, Paul Neeson, PhD

Blood (2013) 122 (21): 1904.

https://doi.org/10.1182/blood.V122.21.1904.1904

Published: 2013

Journal Articles

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

Pearlie K Epling-Burnette, PhD, Ying Han, MD, Adam W Mailloux, PhD, Ling Zhang, MD, Jessica M. McDaniel, PhD, Rajadhyaksha Anjali, PhD, Sheng Wei, MD, Ritchie David, PhD, Paul Neeson, PhD, Rami S. Komrokji, MD, Alan List, MD

Blood (2013) 122 (21): 748.

https://doi.org/10.1182/blood.V122.21.748.748

Published: 2013

Journal Articles

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Simon J. Harrison, Hang Quach, Emma Link, John F. Seymour, David S. Ritchie, Sam Ruell, Joanne Dean, Henry Januszewicz, Ricky Johnstone, Paul Neeson, Michael Dickinson, Jean Nichols, H. Miles Prince

Blood (2011) 118 (24): 6274–6283.

https://doi.org/10.1182/blood-2011-03-339879

Published: 2011

Includes: Supplemental data

Journal Articles

Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis y Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,

Paul Neeson, PhD, Amit S Khot, MBBS, MD, MRCP, FRCPath, Stefan Peinert, MD, Tsin Y Tai, MSc, Karen Chen, Kellie Tainton, BSc, Dominic Wall, PhD, Dirk Hoenemann, MD, Michael H Kershaw, PhD, Jennifer Westwood, Joe Trapani, PhD, Mark J Smyth, PhD, Phillip Darcy, PhD, Andrew Scott, PhD, Lucy Kravets, BSc, Jill Davison, RN, Michael J. Dickinson, MBBS, FRACP, FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2011) 118 (21): 4180.

https://doi.org/10.1182/blood.V118.21.4180.4180

Published: 2011

Journal Articles

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Amit S Khot, MBBS, MD, MRCP (UK), FRCPath, Tsin Tsin, Andy Hsu, PhD, Karen Chen, Maureen Loudovaris, Paul Neeson, PhD, Dominic Wall, PhD, Rebecca Sedunary, H. Miles Prince, MBBS, FRACP, FRCPA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD

Blood (2011) 118 (21): 1862.

https://doi.org/10.1182/blood.V118.21.1862.1862

Published: 2011

Journal Articles

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Andy K. Hsu, Hang Quach, Tsin Tai, H. Miles Prince, Simon J. Harrison, Joseph A. Trapani, Mark J. Smyth, Paul Neeson, David S. Ritchie

Blood (2011) 117 (5): 1605–1613.

https://doi.org/10.1182/blood-2010-04-278432

Published: 2011

Includes: Supplemental data

Journal Articles

N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties

Jake Shortt, FRACP, FRCPA, Andy Hsu, PhD, Geoffrey M Matthews, PhD, Marta Chesi, P.Leif Bergsagel, MD, Grant A. McArthur, MD, PhD, FRACP, MBBS, Paul Neeson, PhD, David Ritchie, MBBS, FRACP, FRCPA, Ricky W Johnstone, PhD

Blood (2010) 116 (21): 4082.

https://doi.org/10.1182/blood.V116.21.4082.4082

Published: 2010

Journal Articles

In Vivo Antagonistic Effects of Dexamethasone On Lenalidomide-Induced NK Cell Activation.

Hang Quach, FRACP, Hsu Andy, MSc, David Ritchie, PhD, Paul Neeson, PhD, Kevin Lynch, MB, BS, Simon Harrison, PhD, Miles Prince, MD

Blood (2009) 114 (22): 1639.

https://doi.org/10.1182/blood.V114.22.1639.1639

Published: 2009

Journal Articles

In Vitro Efficacy of Agonistic Antibody to TRAIL-R1 (Mapatumumab) and Low Dose Bortezomib in Multiple Myeloma

Paul Neeson, PhD, Karen Chen, Tsin Tai, MSc, Amanda Shin, Joanne Davis, PhD, H. Miles Prince, MD, David S. Ritchie, MD, PhD

Blood (2008) 112 (11): 5169.

https://doi.org/10.1182/blood.V112.11.5169.5169

Published: 2008

Journal Articles

The Level of Glycolytic Metabolism of AML Blasts May Predict Drug Sensitivity and Prognosis in Patients with AML

D. Ritchie, Paul Neeson, PhD, Michael V Berridge, PhD, MSc, BSc, Patries Herst

Blood (2008) 112 (11): 4022.

https://doi.org/10.1182/blood.V112.11.4022.4022

Published: 2008

Journal Articles

Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).

Hang Quach, MB, BS, FRACP, FRCPA, David Ritchie, MBChB, FRACP, FRCPA, PhD, Paul Neeson, PhD, Simon Harrison, MB, BS, MRCP, MRCPath, PhD, Tsin Tai, MSc, Kellie Tainton, BSc, Kevin Lynch, MB, BS, FFPM, Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD

Blood (2008) 112 (11): 1696.

https://doi.org/10.1182/blood.V112.11.1696.1696

Published: 2008

Journal Articles

Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype

Stefan Peinert, David S. Ritchie, Dirk Hoenemann, Simon J. Harrison, Preethi Guru, Michael H. Kershaw, Amanda Shin, Mark J. Smyth, Joseph A. Trapani, Andrew M Scott, Glenn A Cartwright, Fiona E Smyth, Barbara E Power, Phillip K. Darcy, Peter Gambell, David Westerman, Paul Neeson, H. Miles Prince

Blood (2008) 112 (11): 3900.

https://doi.org/10.1182/blood.V112.11.3900.3900

Published: 2008

Journal Articles

Gene-Modified CD8+ T Cells Undergo Functional Polarization to Effector and Central Memory Cells in Response to Antigen Exposure.

Paul Neeson, PhD, Amanda Shin, Tsin Tai, MSc, Karen Chen, Joanne Davis, Kellie Tainton, BSc, Phil Darcy, PhD, Michael H. Kershaw, Stefan Peinert, Preethi Guru, Simon Harrison, H. Miles Prince, D. Ritchie

Blood (2008) 112 (11): 1531.

https://doi.org/10.1182/blood.V112.11.1531.1531

Published: 2008

Journal Articles

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, MBBS, Hang Quach, MBBS, Paul Neeson, MBBS, Mitch Keegan, Michael Copeman, MBBS, Stefan Peinert, MBBS, Mark Bishton, MBBS, Max Wolf, MBBS, David Ritchie, MBBS, John F. Seymour, MBBS, Dennis Carney, MBBS, David Westerman, MBBS, Simon Harrison, MBBS

Blood (2007) 110 (11): 1167.

https://doi.org/10.1182/blood.V110.11.1167.1167

Published: 2007

NARROW

Allogeneic CAR19 cells clear ALL

CAR-T Cells Are Serial Killers of Tumor Cells

Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation and Onset of Gvhd

Histone Deacteylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells

CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicty

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis y Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties

In Vivo Antagonistic Effects of Dexamethasone On Lenalidomide-Induced NK Cell Activation.

In Vitro Efficacy of Agonistic Antibody to TRAIL-R1 (Mapatumumab) and Low Dose Bortezomib in Multiple Myeloma

The Level of Glycolytic Metabolism of AML Blasts May Predict Drug Sensitivity and Prognosis in Patients with AML

Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).

Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype

Gene-Modified CD8+ T Cells Undergo Functional Polarization to Effector and Central Memory Cells in Response to Antigen Exposure.

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only